Walleye Capital LLC Takes $490,000 Position in Artivion, Inc. $AORT

Walleye Capital LLC bought a new position in shares of Artivion, Inc. (NYSE:AORT) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 21,825 shares of the company’s stock, valued at approximately $490,000.

Other hedge funds have also recently bought and sold shares of the company. Glenmede Trust Co. NA acquired a new stake in shares of Artivion in the 1st quarter valued at $295,000. Bank of America Corp DE boosted its position in Artivion by 0.8% in the first quarter. Bank of America Corp DE now owns 522,515 shares of the company’s stock valued at $19,135,000 after buying an additional 3,980 shares in the last quarter. Amundi boosted its position in Artivion by 7.5% in the first quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after buying an additional 501 shares in the last quarter. California State Teachers Retirement System grew its stake in Artivion by 33.4% during the first quarter. California State Teachers Retirement System now owns 51,213 shares of the company’s stock worth $1,875,000 after buying an additional 12,825 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in Artivion by 73.1% during the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock worth $3,430,000 after buying an additional 39,553 shares during the last quarter. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Canaccord Genuity Group set a $39.00 price objective on shares of Artivion in a report on Friday, August 7th. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday. Citizens Jmp dropped their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Finally, Stifel Nicolaus set a $45.00 price objective on Artivion in a research report on Monday, June 1st. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and an average target price of $44.67.

Insiders Place Their Bets

In other news, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. This trade represents a 0.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the sale, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This trade represents a 42.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.30% of the company’s stock.

Artivion Stock Up 2.8%

Shares of NYSE AORT opened at $29.22 on Friday. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The firm’s 50-day moving average is $24.28 and its 200-day moving average is $30.59. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.42 billion, a PE ratio of -417.33 and a beta of 1.25.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. The business had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Equities analysts expect that Artivion, Inc. will post 0.45 EPS for the current year.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.